Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2007:804–836. [Article in German] doi: 10.1007/978-3-540-76460-1_100

Virale Infektionen

J Forster 5, V Schuster 6, H W Kreth 7, D Nadal 8, H -J Schmitt 9
Editors: Michael J Lentze1, Franz J Schulte2, Jürgen Schaub3, Jürgen Spranger4
PMCID: PMC7120150

Auszug

Adenoviren verursachen im Kindesalter Krankheiten der Atemwege und des Darms, aber auch Krankheiten der Harnwege, der Lymphorgane und kardiologische und neurologische Manifestationen werden beobachtet. Einige typische Krankheitsbilder können klinisch diagnostiziert werden.

Literatur

Literatur

  1. Brandt C.D., Kim H.W., Vargosko A.J., et al. Infections in 18,000 infants and children in a controlled study of respiratory tract disease. I. Adenovirus pathogenicity in relation to sérologic type and illness syndrome. Am J Epidemiol. 1969;90:484–500. doi: 10.1093/oxfordjournals.aje.a121094. [DOI] [PubMed] [Google Scholar]
  2. Hoffman J.A., Shah A.J., Ross L.A., Kapoor N. Adenoviral infections and a prospective trial of cidofovir in pediatric hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2001;7:388–394. doi: 10.1053/bbmt.2001.v7.pm11529489. [DOI] [PubMed] [Google Scholar]
  3. McCarthy A.J., Bergin M., de Silva L.M., Stevens M. Intravenous ribavirin therapy for disseminated adenovirus infection. Pediatr Infect Dis J. 1995;14:1003–1004. doi: 10.1097/00006454-199511000-00017. [DOI] [PubMed] [Google Scholar]
  4. Schleuning M., Buxbaum-Conradi H., Jager G., Kolb H.J. Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants. Hematol J. 2004;5:135–144. doi: 10.1038/sj.thj.6200358. [DOI] [PubMed] [Google Scholar]
  5. Watzinger F., Suda M., Preuner S., et al. Real-time quantitative PCR assays for detection and monitoring of pathogenic human viruses in immunosuppressed pediatric patients. J Clin Microbiol. 2004;42:5189–5198. doi: 10.1128/JCM.42.11.5189-5198.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]

Literatur

  1. Gern J.E., Galagan D.M., Jarjour N.N., et al. Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. Am J Respir Crit Care Med. 1997;155:1159–1161. doi: 10.1164/ajrccm.155.3.9117003. [DOI] [PubMed] [Google Scholar]
  2. Jartti T., Lehtinen P., Vuorinen T., et al. Respiratory picornaviruses and respiratory syncytial virus as causative agents of acute expiratory wheezing in children. Emerg Infect Dis. 2004;10:1095–1101. doi: 10.3201/eid1006.030629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kling S., Donninger H., Williams Z., et al. Persistence of rhinovirus RNA after asthma exacerbation in children. Clin Exp Allergy. 2005;35:672–678. doi: 10.1111/j.1365-2222.2005.02244.x. [DOI] [PubMed] [Google Scholar]
  4. Korppi M., Kotaniemi-Syrjanen A., Waris M., et al. Rhinovirus-associated wheezing in infancy: comparison with respiratory syncytial virus bronchiolitis. Pediatr Infect Dis J. 2004;23:995–999. doi: 10.1097/01.inf.0000143642.72480.53. [DOI] [PubMed] [Google Scholar]
  5. Turner R.B. Epidemiology, pathogenesis, and treatment of the common cold. Ann Allergy Asthma Immunol. 1997;78:531–539. doi: 10.1016/S1081-1206(10)63213-9. [DOI] [PMC free article] [PubMed] [Google Scholar]

Literatur

  1. Abzug M.J., Cloud G., Bradley J.., National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group et al. Double blind placebo-controlled trial of pleconaril in infants with enterovirus meningitis. Pediatr Infect Dis J. 2003;22:335–341. doi: 10.1097/01.inf.0000059765.92623.70. [DOI] [PubMed] [Google Scholar]
  2. Jartti T., Lehtinen P., Vuorinen T., et al. Respiratory picornaviruses and respiratory syncytial virus as causative agents of acute expiratory wheezing in children. Emerg Infect Dis. 2004;10:1095–1101. doi: 10.3201/eid1006.030629. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Kearns G.L., Bradley J.S., Jacobs R.F., et al. Single dose pharmacokinetics of pleconaril in neonates. Pediatric Pharmacology Research Unit Network. Pediatr Infect Dis J. 2000;19:833–839. doi: 10.1097/00006454-200009000-00005. [DOI] [PubMed] [Google Scholar]
  4. Sawyer M.H. Enterovirus infections: diagnosis and treatment. Semin Pediatr Infect Dis. 2002;13:40–47. doi: 10.1053/spid.2002.29756. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Bueving H.J., Bernsen R.M., de Jongste J.C., et al. Influenza vaccination in children with asthma: randomized double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2004;169:488–493. doi: 10.1164/rccm.200309-1251OC. [DOI] [PubMed] [Google Scholar]
  2. Cooper N.J., Sutton A.J., Abrams K.R., et al. Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials. BMJ. 2003;326:1235. doi: 10.1136/bmj.326.7401.1235. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Denison M.R. Severe acute respiratory syndrome coronavirus pathogenesis, disease and vaccines: an update. Pediatr Infect Dis J. 2004;23:S207–214. doi: 10.1097/01.inf.0000144666.95284.05. [DOI] [PubMed] [Google Scholar]
  4. Jefferson T., Smith S., Demicheli V., et al. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet. 2005;365:773–780. doi: 10.1016/S0140-6736(05)71000-X. [DOI] [PubMed] [Google Scholar]
  5. Johnston S.L., Ferrero F., Garcia M.L., Dutkowski R. Oral oseltamivir improves pulmonary function and reduces exacerbation frequency for influenza-infected children with asthma. Pediatr Infect Dis J. 2005;24:225–232. doi: 10.1097/01.inf.0000154322.38267.ce. [DOI] [PubMed] [Google Scholar]
  6. Uyeki T.M. Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza. Pediatr Infect Dis J. 2003;22:164–177. doi: 10.1097/01.inf.0000050458.35010.b6. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Knott A.M., Long C.E., Hall C.B. Parainfluenza viral infections in pediatric outpatients: seasonal patterns and clinical characteristics. Pediatr Infect Dis J. 1994;13:269–273. doi: 10.1097/00006454-199404000-00005. [DOI] [PubMed] [Google Scholar]
  2. Lindquist S.W., Darnule A., Istas A., Demmler G.J. Parainfluenza virus type 4 infections in pediatric patients. Pediatr Infect Dis J. 1997;16:34–38. doi: 10.1097/00006454-199701000-00008. [DOI] [PubMed] [Google Scholar]
  3. Marx A., Török T.J., Holman R.C., et al. Pediatric hospitalizations for croup (laryngotracheobronchitis): biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis. 1997;176:1423–1427. doi: 10.1086/514137. [DOI] [PubMed] [Google Scholar]
  4. Reed G., Jewett P.H., Thompson J., et al. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J Infect Dis. 1997;175:807–813. doi: 10.1086/513975. [DOI] [PubMed] [Google Scholar]
  5. Williams J.V., Harris P.A., Tollefson S.J., et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004;350:443–450. doi: 10.1056/NEJMoa025472. [DOI] [PMC free article] [PubMed] [Google Scholar]

Literatur

  1. Anderson L.J., Heilman C.A. Protective and disease-enhancing immune responses to respiratory syncytial virus. J Infect Dis. 1995;171:1–7. doi: 10.1093/infdis/171.1.1. [DOI] [PubMed] [Google Scholar]
  2. Feltes T.F., Cabalka A.K., Meissner H.C.., Cardiac Synagis Study Group et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr. 2003;143:532–540. doi: 10.1067/S0022-3476(03)00454-2. [DOI] [PubMed] [Google Scholar]
  3. IMpact-RSV Study Group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics. 1998;102:531–537. doi: 10.1542/peds.102.3.531. [DOI] [PubMed] [Google Scholar]
  4. Hall C.B. Respiratory syncytial virus. In: Feigin R.D., Cherry J.D., editors. Textbook of pediatric infectious diseases. 4th edn. Philadelphia: Saunders; 1998. pp. 2084–2111. [Google Scholar]
  5. Wang E.E., Law B.J., Stephens D. Pediatric Investigators Collaborative Network on Infections in Canada (PICNIC) prospective study of risk factors and outcomes in patients hospitalized with respiratory syncytial viral lower respiratory tract infection. J Pediatr. 1995;126:212–219. doi: 10.1016/S0022-3476(95)70547-3. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Crowe J.E., Jr. Human metapneumovirus as a major cause of human respiratory tract disease. Pediatr Infect Dis J. 2004;23([Suppl 11]):S215–221. doi: 10.1097/01.inf.0000144668.81573.6d. [DOI] [PubMed] [Google Scholar]
  2. van den Hoogen B.G., de Jong J.C., Groen J., et al. A newly discovered human pneumovirus isolated from young children with respiratory tract disease. Nat Med. 2001;7:719–724. doi: 10.1038/89098. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. König B., König W., Arnold R., et al. Prospective study of human metapneumovirus infection in children less than 3 years of age. J Clin Microbiol. 2004;42:4632–4635. doi: 10.1128/JCM.42.10.4632-4635.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Williams J.V., Harris P.A., Tollefson S.J., et al. Human metapneumovirus and lower respiratory tract disease in otherwise healthy infants and children. N Engl J Med. 2004;350:443–450. doi: 10.1056/NEJMoa025472. [DOI] [PMC free article] [PubMed] [Google Scholar]

Literatur

  1. Arenz S., Schmitt H.J., Tischer A., von Kries R. Effectiveness of measles vaccination after household exposure during a measles outbreak: a household contact study in Coburg, Bavaria. Pediatr Infect Dis J. 2005;24:697–699. doi: 10.1097/01.inf.0000172900.70430.c2. [DOI] [PubMed] [Google Scholar]
  2. Avota E., Avots A., Niewiesk S., et al. Disruption of Akt Kinase activation is important for immunosuppression induced by measles virus. Nat Med. 2001;7:725–731. doi: 10.1038/89106. [DOI] [PubMed] [Google Scholar]
  3. Brodsky A.L. Atypical measles: severe illness in recipients of killed measles virus vaccine upon exposure to natural infection. JAMA. 1972;222:1415–1416. doi: 10.1001/jama.1972.03210110051014. [DOI] [PubMed] [Google Scholar]
  4. Coutsoudis A., Broughton M., Coovadia H.H. Vitamin A supplementation reduces measles morbidity in young African children: a randomized placebo-controlled, double-blind trial. Am J Clin Nutr. 1991;54:890–895. doi: 10.1093/ajcn/54.5.890. [DOI] [PubMed] [Google Scholar]
  5. Forni A.L., Schluger N.W., Robert R.B. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin Infect Dis. 1994;19:454–462. doi: 10.1093/clinids/19.3.454. [DOI] [PubMed] [Google Scholar]
  6. Gendelman K.E., Wolinsky J.S., Johnson R.T., et al. Measles encephalitis: lack of evidence of viral invasion of the central nervous system and quantitative study of the nature of demyelination. Ann Neurol. 1984;15:353–360. doi: 10.1002/ana.410150409. [DOI] [PubMed] [Google Scholar]
  7. Markowitz L.E., Chandler F.W., Roldan E.O., et al. Fatal measles pneumonia without rash in a child with AIDS. J Infect Dis. 1988;158:480–483. doi: 10.1093/infdis/158.2.480. [DOI] [PubMed] [Google Scholar]
  8. Mustafa M.M., Weitman S.D., Winick N.J., et al. Subacute measles encephalitis in the young immunocompromised host: report of two cases diagnosed by polymerase chain reaction and treated with ribavirin and review of the literature. Clin Infect Dis. 1993;16:654–660. doi: 10.1093/clind/16.5.654. [DOI] [PubMed] [Google Scholar]
  9. Perry R.T., Halsey N.A. The clinical significance of measles: a review. J Infect Dis. 2004;189([Suppl 1]):S4–16. doi: 10.1086/377712. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Belay E.D., Holman R.C., Schonberger L.B. Creutzfeldt-Jakob disease surveillance and diagnosis. Clin Infect Dis. 2005;41:834–836. doi: 10.1086/432726. [DOI] [PubMed] [Google Scholar]
  2. Bellini W.J., Rota J.S., Lowe L.E., et al. Subacute sclerosing panencephalitis: more cases of this fatal disease are prevented by measles immunization than was previously recognized. J Infect Dis. 2005;192:1686–1693. doi: 10.1086/497169. [DOI] [PubMed] [Google Scholar]
  3. Brown P. Human growth hormone therapy and Creutzfeldt-Jakob disease: a drama in three acts. Pediatrics. 1988;81:85–92. [PubMed] [Google Scholar]
  4. Domes K. New aspects in the pathogenesis of polyomavirus-induced disease. Adv Virus Res. 1997;48:205–261. doi: 10.1016/S0065-3527(08)60289-4. [DOI] [PubMed] [Google Scholar]
  5. Flechsig E., Weissmann C. The role of PrP in health and disease. Curr Mol Med. 2004;4:337–353. doi: 10.2174/1566524043360645. [DOI] [PubMed] [Google Scholar]
  6. Hosoya M., Mori S., Tomoda A., et al. Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis. Antimicrob Agents Chemother. 2004;48:4631–4635. doi: 10.1128/AAC.48.12.4631-4635.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kretzschmar H. Transmissible spongiforme Enzephalopathien (Prionkrankheiten) In: Hopf H.C., Deuschl G., Diener H.C., editors. Neurologie in Praxis und Klinik. 2. Aufl. Stuttgart: Thieme; 1999. [Google Scholar]
  8. Langer-Gould A., Atlas S.W., Green A.J., et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353:375–381. doi: 10.1056/NEJMoa051847. [DOI] [PubMed] [Google Scholar]
  9. Martin R., Marquardt P., O’Shea S., et al. Virus specific and autoreactive T cell lines isolated from cerebrospinal fluid of a patient with chronic rubella panencephalitis. J Neuroimmunol. 1989;23:1–10. doi: 10.1016/0165-5728(89)90065-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Miller C., Farrington C.P., Harbert K. The epidemiology of subacute sclerosing panencephalitis in England and Wales 1970–1989. Int J Epidemiol. 1992;21:998–1006. doi: 10.1093/ije/21.5.998. [DOI] [PubMed] [Google Scholar]
  11. Nasemann J.E., Schmid C., Schneider A., et al. Äußere Retinitis als Frühsymptom bei subakut sklerosierender Panenzephalitis (SSPE) Klin Monatsbl Augenheilkd. 1996;206:122–127. doi: 10.1055/s-2008-1035415. [DOI] [PubMed] [Google Scholar]
  12. Prusiner S.B. Molecular biology of prion diseases. Science. 1991;252:1515–1522. doi: 10.1126/science.1675487. [DOI] [PubMed] [Google Scholar]
  13. Redfearn A., Pennie R.A., Mahony J.B., Dent P.B. Progressive multifocal leukoencephalopathy in a child with immunodeficiency and hyperimmunoglobulinemia M. Pediatr Infect Dis J. 1993;12:399–401. doi: 10.1097/00006454-199305000-00010. [DOI] [PubMed] [Google Scholar]
  14. Steelman V.M. Creutzfeldt-Jakob disease: recommendations for infection control. Am J Infect Control. 1994;22:312–318. doi: 10.1016/0196-6553(94)90019-1. [DOI] [PubMed] [Google Scholar]
  15. Vandersteenhoven J.J., Dbaibo G., Boyko O.B., et al. Progressive multifocal leukoencephalopathy in pediatric acquired immunodeficiency syndrome. Pediatr Infect Dis J. 1992;11:232–237. doi: 10.1097/00006454-199203000-00013. [DOI] [PubMed] [Google Scholar]
  16. Will R.G., Ironside J.W., Zeidler M., et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347:921–925. doi: 10.1016/S0140-6736(96)91412-9. [DOI] [PubMed] [Google Scholar]
  17. Zwiauer K., Forstenpointner E., Popow-Kraupp T., et al. Rapid progressive subacute sclerosing panencephalitis after perinatally acquired measles virus infections. Lancet. 1995;345:1124. doi: 10.1016/S0140-6736(95)90858-7. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Bayer W.L., Sherman F.E., Michaels R.H., et al. Purpura in congenital and acquired rubella. N Engl J Med. 1965;273:1362–1366. doi: 10.1056/NEJM196512162732504. [DOI] [PubMed] [Google Scholar]
  2. Bitzan M. Rubella myelitis and encephalitis in childhood. A report of two cases with magnetic resonance imaging. Neuropediatrics. 1987;18:84–87. doi: 10.1055/s-2008-1052458. [DOI] [PubMed] [Google Scholar]
  3. Dwyer D.E., Hueston L., Field P.R., et al. Acute encephalitis complicating rubella virus infection. Pediatr Infect Dis J. 1992;11:238–240. doi: 10.1097/00006454-199203000-00014. [DOI] [PubMed] [Google Scholar]
  4. Enders G., Knotek F. Rubella IgG total antibody avidity and IgG subclass-specific antibody avidity assay and their role in the differentiation between primary rubella and rubella reinfection. Infection. 1989;17:218–226. doi: 10.1007/BF01639523. [DOI] [PubMed] [Google Scholar]
  5. Frenkel L.M., Nielsen K., Garakian A., et al. A search for persistent rubella virus infection in persons with chronic symptoms after rubella and rubella immunization and in patients with juvenile rheumatoid arthritis. Clin Infect Dis. 1996;22:287–294. doi: 10.1093/clinids/22.2.287. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Casella R., Leibundgut B., Lehmann K., Gasser T.C. Mumps orchitis: report of a mini-epidemic. J Urol. 1997;158:2158–2161. doi: 10.1016/S0022-5347(01)68186-2. [DOI] [PubMed] [Google Scholar]
  2. Hall R., Richards H. Hearing loss due to mumps. Arch Dis Child. 1987;62:189–192. doi: 10.1136/adc.62.2.189. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Helmke K., Often A., Willems W.R., et al. Islet cell antibodies and the development of diabetes mellitus in relation to mumps infection and mumps vaccination. Diabetologia. 1986;29:30–33. doi: 10.1007/BF02427277. [DOI] [PubMed] [Google Scholar]
  4. Hviid A., Stellfeld M., Wohlfahrt J., Melbye M. Childhood vaccination and type 1 diabetes. N Engl J Med. 2004;350:1398–1404. doi: 10.1056/NEJMoa032665. [DOI] [PubMed] [Google Scholar]
  5. Vaheri A., Julkunen I., Koskiniemi M.L. Chronic encephalomyelitis with specific increase in intrathecal mumps antibodies. Lancet. 1982;2:685–688. doi: 10.1016/S0140-6736(82)90713-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Vandvik B., Norrby E., Steen-Johnson J., Stensvold K. Mumps meningitis: prolonged pleocytosis and occurrence of mumps-specific oligoclonal IgG in the cerebrospinal fluid. Eur Neurol. 1978;17:13–22. doi: 10.1159/000114916. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Asano Y., Yoshikawa T., Suga S., et al. Clinical features of infants with primary human herpesvirus 6 infection (exanthem subitum, roseola infantum) Pediatrics. 1994;93:104–108. [PubMed] [Google Scholar]
  2. Caserta M.T., McDermott M.P., Dewhurst S., et al. Human herpesvirus 6 (HHV6) DNA persistence and reactivation in healthy children. J Pediatr. 2004;145:478–484. doi: 10.1016/j.jpeds.2004.06.016. [DOI] [PubMed] [Google Scholar]
  3. Hall C.B., Caserta M.T., Schnabel K.C., et al. Congenital infections with human herpesvirus 6 (HHV6) and human herpesvirus 7 (HHV7) J Pediatr. 2004;145:472–477. doi: 10.1016/j.jpeds.2004.06.017. [DOI] [PubMed] [Google Scholar]
  4. Suga S., Suzuki K., Ihira M., et al. Clinical characteristics of febrile convulsions during primary HHV-6 infection. Arch Dis Child. 2000;82:62–66. doi: 10.1136/adc.82.1.62. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Tokimasa S., Hara J., Osugi Y., et al. Ganciclovir is effective for prophylaxis and treatment of human herpesvirus-6 in allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29:595–598. doi: 10.1038/sj.bmt.1703423. [DOI] [PubMed] [Google Scholar]
  6. Ward K.N., Andrews N.J., Verity C.M., et al. Human herpesviruses-6 and-7 each cause significant neurological morbidity in Britain and Ireland. Arch Dis Child. 2005;90:619–623. doi: 10.1136/adc.2004.062216. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Yoshihara S., Kato R., Inoue T., et al. Successful treatment of life-threatening human herpesvirus-6 encephalitis with donor lymphocyte infusion in a patient who had undergone human leukocyte antigen-haploidentical nonmyeloablative stem cell transplantation. Transplantation. 2004;77:835–838. doi: 10.1097/01.TP.0000119603.59880.47. [DOI] [PubMed] [Google Scholar]
  8. Zerr D.M., Meier A.S., Selke S.S., et al. A population-based study of primary human herpesvirus 6 infection. N Engl J Med. 2005;352:768–776. doi: 10.1056/NEJMoa042207. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Boutolleau D., Fernandez C., Andre E., et al. Human herpesvirus (HHV)-6 and HHV-7: two closely related viruses with different infection profiles in stem cell transplantation recipients. J Infect Dis. 2003;187:179–186. doi: 10.1086/367677. [DOI] [PubMed] [Google Scholar]
  2. Broccolo F., Drago F., Careddu A.M., et al. Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and-7. J Invest Dermatol. 2005;124:1234–1240. doi: 10.1111/j.0022-202X.2005.23719.x. [DOI] [PubMed] [Google Scholar]
  3. Caserta M.T., Hall C.B., Schnabel K., et al. Primary human herpesvirus 7 infection: a comparisation of human herpesvirus 7 and human herpesvirus 6 infections in children. J Pediatr. 1998;133:386–389. doi: 10.1016/S0022-3476(98)70275-6. [DOI] [PubMed] [Google Scholar]
  4. Chan P.K., Li C.K., Chik K.W., et al. Risk factors and clinical consequences of human herpesvirus 7 infection in paediatric haematopoietic stem cell transplant recipients. J Med Virol. 2004;72:668–674. doi: 10.1002/jmv.20032. [DOI] [PubMed] [Google Scholar]
  5. Levy J.A. Three new human herpesviruses (HHV6, 7, and 8) Lancet. 1997;349:558–563. doi: 10.1016/S0140-6736(97)80119-5. [DOI] [PubMed] [Google Scholar]
  6. Takahashi Y., Yamada M., Nakamura J., et al. Transmission of human herpesvirus 7 through multigenerational families in the same household. Pediatr Infect Dis J. 1997;16:975–978. doi: 10.1097/00006454-199710000-00014. [DOI] [PubMed] [Google Scholar]
  7. Torigoe S., Kumamoto T., Koide W., et al. Clinical manifestations associated with human herpesvirus 7 infection. Arch Dis Child. 1995;72:518–519. doi: 10.1136/adc.72.6.518. [DOI] [PMC free article] [PubMed] [Google Scholar]

Literatur

  1. Bhaduri-Mclntosh S. Human herpesvirus-8: clinical features of an emerging viral pathogen. Pediatr Infect Dis J. 2005;24:81–82. doi: 10.1097/01.inf.0000151367.14455.9c. [DOI] [PubMed] [Google Scholar]
  2. Camcioglu Y., Picard C., Lacoste V., et al. HHV-8-associated Kaposi sarcoma in a child with IFNgammaRl deficiency. J Pediatr. 2004;144:519–523. doi: 10.1016/j.jpeds.2003.11.012. [DOI] [PubMed] [Google Scholar]
  3. Chen R.L., Lin J.C., Wang P.J., et al. Human herpesvirus 8-related childhood mononucleosis: a series of three cases. Pediatr Infect Dis J. 2004;23:671–674. doi: 10.1097/01.inf.0000128776.45784.80. [DOI] [PubMed] [Google Scholar]
  4. Plancoulaine S., Abel L., van Beveren M., et al. Human herpesvirus 8 transmission from mother to child and between siblings in an endemic population. Lancet. 2000;356:1062–1065. doi: 10.1016/S0140-6736(00)02729-X. [DOI] [PubMed] [Google Scholar]
  5. Wheat W.H., Cool C.D., Morimoto Y., et al. Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J Exp Med. 2005;202:479–484. doi: 10.1084/jem.20050381. [DOI] [PMC free article] [PubMed] [Google Scholar]

Literatur

  1. Anderson M.J., Higgins P.G., David L.R., et al. Experimental parvoviral infection in humans. J Infect Dis. 1985;152:257–265. doi: 10.1093/infdis/152.2.257. [DOI] [PubMed] [Google Scholar]
  2. Brown K.E., Hibbs J.R., Gallinella G., et al. Resistance to parvovirus B19 infection due to lack of virus receptor (erythrocyte P antigen) N Engl J Med. 1994;330:1192–1196. doi: 10.1056/NEJM199404283301704. [DOI] [PubMed] [Google Scholar]
  3. Heegaard E.D., Hornsleth A. Parvovirus: the expanding spectrum of disease. ActaPaediatr. 1995;84:109–117. doi: 10.1111/j.1651-2227.1995.tb13591.x. [DOI] [PubMed] [Google Scholar]
  4. Lehmann H.W., von Landenberg P., Modrow S. Parvovirus B19 infection and autoimmune disease. Autoimmun Rev. 2003;2:218–223. doi: 10.1016/S1568-9972(03)00014-4. [DOI] [PubMed] [Google Scholar]
  5. Levy R., Weissman A., Blomberg G., Hagy Z.J. Infection by parvovirus B19 during pregnancy: a review. Obstet Gynecol Surv. 1997;52:254–259. doi: 10.1097/00006254-199704000-00023. [DOI] [PubMed] [Google Scholar]
  6. Servant A., Laperche S., Lallemand F., et al. Genetic diversity within human erythroviruses: identification of three genotypes. J Virol. 2002;76:9124–9134. doi: 10.1128/JVI.76.18.9124-9134.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Young N.S., Brown K.E. Parvovirus B19. N Engl J Med. 2004;350:586–597. doi: 10.1056/NEJMra030840. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Kimura H., Aso K., Kuzushima K., et al. Relapse of herpes simplex encephalitis in children. Pediatrics. 1992;89:891–894. [PubMed] [Google Scholar]
  2. Schuster V., Handrick W., Korn K., et al. et al. Herpes-simplex-Virus-Infektionen. In: Scholz H., Belohradsky B.H., Heininger U., et al.et al., editors. Handbuch Infektionen bei Kindern und Jugendlichen. 5. Aufl. München: DGPI/Futuramed; 2007. [Google Scholar]
  3. Wagstaff A.J., Faulds D., Goa K.L. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. Drugs. 1994;47:153–205. doi: 10.2165/00003495-199447010-00009. [DOI] [PubMed] [Google Scholar]
  4. Kimberlin D. Herpes simplex virus, meningitis and encephalitis in neonates (review) Herpes. 2004;11([Suppl2]):65A–76A. [PubMed] [Google Scholar]

Literatur

  1. Enders G., Miller E., Cradock-Watson J., et al. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet. 1994;343:1548–1551. doi: 10.1016/S0140-6736(94)92943-2. [DOI] [PubMed] [Google Scholar]
  2. Gilden D. Varicella zoster virus and central nervous system syndromes. Herpes. 2004;11([Suppl 2]):89A–94A. [PubMed] [Google Scholar]
  3. Leung T.F., Chik K.W., Li C.K., et al. Incidence, risk factors and outcome of varicella-zoster virus infection in children after haematopoietic stem cell transplantation. Bone Marrow Transplant. 2000;25:167–172. doi: 10.1038/sj.bmt.1702119. [DOI] [PubMed] [Google Scholar]
  4. Lin T.Y., Huang Y.C., Ning H.C., Hsueh C. Oral acyclovir prophylaxis of varicella after intimate contact. Pediatr Infect Dis J. 1997;16:1162–1165. doi: 10.1097/00006454-199712000-00012. [DOI] [PubMed] [Google Scholar]
  5. Ozaki T., Kajita Y., Asano Y., et al. Detection of varicella-zoster virus DNA in blood of children with varicella. J Med Virol. 1994;44:263–265. doi: 10.1002/jmv.1890440309. [DOI] [PubMed] [Google Scholar]
  6. Wutzler P., Färber I., Wagenpfeil S., et al. Seroprevalence of varicellazoster virus in the German population. Vaccine. 2001;20:121–124. doi: 10.1016/S0264-410X(01)00276-6. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Boppana S.B., Pass R.F., Britt W.J., et al. Symptomatic congenital cytomegalovirus infection: neonatal morbidity and mortality. Pediatr Infect Dis J. 1992;11:93–99. doi: 10.1097/00006454-199202000-00007. [DOI] [PubMed] [Google Scholar]
  2. Fowler K.B., Stagno S., Pass R.F., et al. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N Engl J Med. 1992;326:663–667. doi: 10.1056/NEJM199203053261003. [DOI] [PubMed] [Google Scholar]
  3. Frenkel L.M., Capparelli E.V., Dankner W.M., et al. Oral ganciclovir in children: pharmacokinetics, safety, tolerance, and antiviral effects. The Pediatric AIDS Clinical Trials Group. J Infect Dis. 2000;182:1616–1624. doi: 10.1086/317600. [DOI] [PubMed] [Google Scholar]
  4. Hamprecht K., Maschmann J., Muller D., et al. Cytomegalovirus (CMV) inactivation in breast milk: reassessment of pasteurization and freeze-thawing. Pediatr Res. 2004;56:529–535. doi: 10.1203/01.PDR.0000139483.35087.BE. [DOI] [PubMed] [Google Scholar]
  5. Kimberlin D.W., Lin C.Y., Sanchez P.J., et al. Effect of ganciclovir therapy on hearing in symptomatic congenital cytomegalovirus disease involving the central nervous system: a randomized, controlled trial. J Pediatr. 2003;143:16–25. doi: 10.1016/S0022-3476(03)00192-6. [DOI] [PubMed] [Google Scholar]
  6. Meijer E., Boland G.J., Verdonck L.F. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants. Clin Microbiol Rev. 2003;16:647–657. doi: 10.1128/CMR.16.4.647-657.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Vollmer B., Seibold-Weiger K., Schmitz-Salue C., et al. Postnatally acquired cytomegalovirus infection via breast milk: effects on hearing and development in preterm infants. Pediatr Infect Dis J. 2004;23:322–327. doi: 10.1097/00006454-200404000-00009. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Callan M.F., Tan L., Anneis N., et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo. J Exp Med. 1998;187:1395–1402. doi: 10.1084/jem.187.9.1395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Clave E., Agbalika F., Bajzik V., et al. Epstein-Barr virus (EBV) reactivation in allogeneic stem-cell transplantation: relationship between viral load, EBV-specific T-cell reconstitution and rituximab therapy. Transplantation. 2004;77:76–84. doi: 10.1097/01.TP.0000093997.83754.2B. [DOI] [PubMed] [Google Scholar]
  3. Gruhn B., Meerbach A., Hafer R., et al. Pre-emptive therapy with rituximab for prevention of Epstein-Barr virus-associated lymphoproliferative disease after hematopoietic stem cell transplantation. Bone Marrow Transplant. 2003;31:1023–1025. doi: 10.1038/sj.bmt.1704061. [DOI] [PubMed] [Google Scholar]
  4. Imashuku S., Hibi S., Ohara T., et al. Effective control of Epstein-Barr virus related hemophagocytic lymphohistiocytosis with immunochemotherapy. Histiocyte Society. Blood. 1999;93:1869–1874. [PubMed] [Google Scholar]
  5. Jenson H.B. Acute complications of Epstein-Barr virus infectious mononucleosis. Curr Opin Pediatr. 2000;12:263–268. doi: 10.1097/00008480-200006000-00016. [DOI] [PubMed] [Google Scholar]
  6. McClain K.L., Leach C.T., Jenson H.B., et al. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med. 1995;332:12–18. doi: 10.1056/NEJM199501053320103. [DOI] [PubMed] [Google Scholar]
  7. Milone M.C., Tsai D.E., Hodinka R.L., et al. Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood. 2005;105:994–996. doi: 10.1182/blood-2004-07-2965. [DOI] [PubMed] [Google Scholar]
  8. Schuster V., Hügle B., Tefs K., Borte M. Atypische Epstein-Barr-Virus (EBV)-Infektionen im Kindes-und Jugendalter. Monatsschr Kinderheilkd. 2002;150:1154–1167. doi: 10.1007/s00112-002-0586-9. [DOI] [Google Scholar]

Literatur

  1. Bielefeldt-Ohmann H. Pathogenesis of dengue virus diseases: missing pieces in the jigsaw. Trends Microbiol. 1997;5:409–413. doi: 10.1016/S0966-842X(97)01126-8. [DOI] [PubMed] [Google Scholar]
  2. Bitzan M. Hämorrhagische Fieber und Hantavirus-Infektionen. In: Deutsche G. f. P. I., editor. Handbuch. Infektionen bei Kindern und Jugendlichen. 2. Aufl. München: Futuramed; 1997. pp. 295–307. [Google Scholar]
  3. Bray M. Pathogenesis of viral hemorrhagic fever. Curr Opinion Immunol. 2005;17:399–403. doi: 10.1016/j.coi.2005.05.001. [DOI] [PubMed] [Google Scholar]
  4. Geisbert T.W., Jahrling P.B. Exotic emerging viral diseases: progress and challenges. Nat Med. 2004;10([Suppl 12]):S110–121. doi: 10.1038/nm1142. [DOI] [PubMed] [Google Scholar]
  5. Kautner I., Robinson M.J., Kuhnle U. Dengue virus infection: epidemiology, pathogenesis, clinical presentation, diagnosis and prevention. J Pediatr. 1997;131:516–524. doi: 10.1016/S0022-3476(97)70054-4. [DOI] [PubMed] [Google Scholar]
  6. Mackenzie J.S., Gubler D.J., Petersen L.R. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med. 2004;10([Suppl 12]):S98–109. doi: 10.1038/nm1144. [DOI] [PubMed] [Google Scholar]
  7. Monath T.P., Cetron M.S. Prevention of yellow fever in persons traveling to the tropics. Clin Infect Dis. 2002;34:1369–1378. doi: 10.1086/340104. [DOI] [PubMed] [Google Scholar]
  8. Pigott D.C. Hemorrhagic fever viruses. Crit Care Clin. 2005;21:765–783. doi: 10.1016/j.ccc.2005.06.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Robertson S.E., Hull B.P., Tomori O., et al. Yellow fever: a decade of reemergence. JAMA. 1996;276:1157–1162. doi: 10.1001/jama.1996.03540140045025. [DOI] [PubMed] [Google Scholar]
  10. Tsai T.F. Ebola and Marburg viruses. In: Long S.S., Pickering L.K., Prober C.G., editors. Pediatric infectious diseases. New York: Churchill Livingstone; 1997. pp. 1274–1275. [Google Scholar]
  11. Tsai T.F. Lymphocytic choriomeningitis virus, Lassa fever virus, and other arenaviruses. In: Long S.S., Pickering L.K., Prober C.G., editors. Pediatric infectious diseases. New York: Churchill Livingstone; 1997. pp. 1275–1278. [Google Scholar]
  12. Willis B.A., Nguyen M.D., Ha T.L., et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med. 2005;353:877–889. doi: 10.1056/NEJMoa044057. [DOI] [PubMed] [Google Scholar]

Literatur

  1. Bear G.M., editor. The natural history of rabies. 2nd edn. Boca Raton/FL: CRC; 1991. [Google Scholar]
  2. Roß R.S., Kruppenbacher J.P., Schiller W.G., et al. Menschliche Tollwuterkrankung in Deutschland. Dtsch Arztebl. 1997;94:29–32. [Google Scholar]

Articles from Pädiatrie are provided here courtesy of Nature Publishing Group

RESOURCES